Englazine, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, has anti-inflammatory and antioxidant effects and can lower the level of HMGB1 and alleviate kidney inflammation in diabetic rats (119). Here, SLC5A2 is linked to inflammation.